Device Trial Radar · NCT04644731
Ultrafiltration Therapy Registry Using Aquadex (ULTRA-Peds)
Last checked: Nov 20, 2026Latest source record: Feb 20, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
97
Actual
Start
Apr 9, 2021
Primary completion
Sep 13, 2023
Study completion Sep 13, 2023
Sponsor
- Lead sponsor
- Nuwellis, Inc.Not on our public-company list
- Sponsor type
- Industry
- Collaborators
- AKI Critical Care Research Foundation
- First posted
- Nov 25, 2020
Design
- Study type
- Observational
- FDA-regulated device
- Yes
- Who can join
- All sexes, up to 21 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The ULTRA-Peds registry will employ a multi-center, single-arm, open-label, observational design to capture baseline, procedural and follow-up data on pediatric patients that have been treated (i.e., retrospective data from treatment at the time of registry approval by the IRB) or are scheduled to be treated (i.e., prospective data for on-label treatment after registry approval by the IRB) with Aquadex therapy according to local standard of care practices and decisions. All prospective data will be from on-label Aquadex treatment of pediatric patients weighing 20 kilograms or more. No data from prospective off-label treatment (i.e., Aquadex treatment with other adjunctive or conjunctive therapies for pediatric patients who may weigh less than 20kg) will be included in the registry. An estimated 10 sites in the United States who have received training in extracorporeal therapy and the Aquadex™ system will enroll a minimum of 500 patients.
Conditions
- Fluid Overload
Interventions
Aquadex™ SystemDevice
Ultrafiltration for fluid removal
Primary outcomes
What the sponsor says the trial is designed to measure.
- Treatment SurvivalTime frame: Through completion of a treatment course, up to 3 months
- Survival at ICU dischargeTime frame: Through completion of a treatment course in the ICU, up to 1 month
- Change in Kidney FunctionTime frame: Change eGFR and renal labs from initiation to completion of treatment, up to 3 months
6 more outcomes with a free account
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
Children's of Alabama Hospital
Birmingham, Alabama
Lucile Packard Children's Hospital Stanford
Palo Alto, California
Joe DiMaggio Children's Hospital
Hollywood, Florida
4 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.